← Back to Clinical Trials
Recruiting NCT07187882

NCT07187882 Autologous Non-cultured Epidermal Cell Suspension Transplantation in the Treatment of Vitiligo

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07187882
Status Recruiting
Phase
Sponsor Peking University People's Hospital
Condition Vitiligo
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2024-04-25
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 8 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Autologous Non-cultured Epidermal Cell Suspension transplantation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2024-04-25 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To observe the long-term efficacy and safety of autologous non cultured epidermal cell suspension transplantation in the treatment of vitiligo, analyze the correlation between cell density, type, and postoperative efficacy and prognosis, and providing a basis for clinical application.

Eligibility Criteria

Inclusion Criteria: * Patients diagnosed as vitiligo, according to the "Vitiligo Diagnosis and Treatment Consensus (2021 edition) * Segmental and unclassified vitiligo stable for 6 months, Non-segmental vitiligo stable for 1 year and resistant to medication and phototherapy * BSA≥5% * Sign the informed consent and be willing to undergo surgical treatment * 8-65 years old, both genders Exclusion Criteria: * Severe visceral or infectious disease not suitable for surgical treatment * Tendency toward keloid formation * Coagulation defects * Unable to complete follow-up on time

Frequently Asked Questions

Who can join the NCT07187882 clinical trial?

This trial is open to participants of all sexes, aged 8 Years or older, up to 65 Years, studying Vitiligo. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07187882 currently recruiting?

Yes, NCT07187882 is actively recruiting participants. Visit ClinicalTrials.gov or contact Peking University People's Hospital to inquire about joining.

Where is the NCT07187882 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT07187882 clinical trial?

NCT07187882 is sponsored by Peking University People's Hospital. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology